




WORLD ODISSEY

CARDIOVASCULAR

DAPAGLIFLOZIN
TRIALS FOR
CHRONIC HEART
FAILURE



CLINICAL TRIALS FRONTIER

Molecule

Indication

Phase

No. of Sites


No. of
Patients

Cardiovascular

MOLECULE	INDICATION	Phase	No. of Sites	No. of Patients
Dapagliflozin	Chronic Heart Failure	III	18	700
Fimasartan Tablets Vs Losartan Tablets	Mild Hypertension	III	22	242
Remogliflozin	Acute Decompensated Heart Failure	III	2	35
Remogliflozin (REMIT-HF)	Chronic Heart Failure	IV	19	250

Dapagliflozin Trials for Chronic Heart Failure

Cardiovascular



Conclusion

The ongoing clinical trials in cardiovascular medicine underscore the continuous efforts to advance therapeutic options for individuals facing various cardiovascular conditions. From Dapagliflozin's potential in chronic heart failure to the comparative study of Fimasartan and Losartan for mild hypertension, and the exploration of Remogliflozin in both acute and chronic heart failure, these trials represent a collective commitment to improving outcomes, enhancing patient care, and addressing the diverse challenges associated with cardiovascular diseases. The outcomes of these trials have the potential to shape the future of cardiovascular medicine, offering new avenues for treatment and care.